Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 305-308

  Hale, G ^a,b   Waldmann, H ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Campath; Graft rejection; GVHD

Indexed keywords

ALEMTUZUMAB;

ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CONFERENCE PAPER; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; MORBIDITY; MORTALITY; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE;

ANTIBODIES; ANTIGENS, CD; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029928384     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Hale G, Waldmann H, for CAMPATH users. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplant 1994; 13: 597-611.
2. Hale G, Waldmann H, for CAMPATH users. Campath-1 monoclonal antibodies in bone marrow transplantation. Hematotherapy 1994; 3: 15-31.
3. Cobbold SP, Martin G, Waldermann H. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: the depletion of T cell subsets in vitro and in vivo. Transplantation 1986; 42: 239-247.
4. Waldmann H, Cobbold S, Hale G. What can be done to prevent graft-versus-host disease? Curr Opin Immunol 1995; 6: 777-783.
5. Bunjes D. Hertenstein B, Wiesneth M et al. In vivo/ex vivo T cell depletion reduces the morbidity of allogeneic bone marrow transplantation in patients with acute leukaemia in first remission without increasing the risk of treatment failure: comparison with cyclosporin/methotrexate. Bone Marrow Transplant 1995; 15: 563-568.
6. Naparstek E, Hardan I, Ben-Shahar H et al. A new method for prevention of graft versus host disease (GVHD). Exp Hematol 1989; 17: 723 (Abstr. 570).
7. Jacobs P, Wood L, Fullard L et al. T cell depletion by exposure to Campath-1 G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994; 13: 763-769.
8. Ringden O, Horowitz M, Sondel P et al. Methotrexate. cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094-1101.
9. Fibbe WE, Falkenburg JHF, Kluin-Nelemans JC et al. Combined use of Campath-1 G in vivo 'in the bag' in allogeneic bone marrow transplantation. Br J Haematol 1994; 87: 128 (abstr.).
10. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
11. Slavin S, Or R, Naparstek E et al. Cellular mediated immunotherapy of leukaemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988; 72 (Suppl.): 407a.
12. Naparstek E, Or R, Nagler A et al. T cell depleted allogeneic bone marrow transplantation for acute leukaemia using CAMPATH-1 antibodies and post-transplant alloimmunization with donor's peripheral blood lymphocytes. Br J Haematol 1995; 89: 506-515.
13. Marks DI, Cullis JO, Ward KN et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207-214.
14. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 1993; 328: 593-602.
15. Dreger P, Viehmann K, Steinmann J et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or Campath-1. Exp Haematol 1995; 23: 147-154.